Gestational trophoblastic disease
Drug research and approvals for gestational trophoblastic disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 9 studies of gestational trophoblastic disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 9
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)NCT07202728 · Not reported · Obstetrics & Gynecology Hospital of Fudan University · starts Jul 9, 2025
- Clinical Specialty Queue For Gestational Trophoblastic NeoplasiaNCT06681259 · Not reported · Women's Hospital School Of Medicine Zhejiang University · starts Nov 4, 2024
- The Psychological Impact of GTN on Women Who Have Completed Chemotherapy TreatmentNCT06169644 · Not reported · Sheffield Teaching Hospitals NHS Foundation Trust · starts May 15, 2024
- Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6NCT06028672 · Not applicable · Peking Union Medical College Hospital · starts Sep 12, 2023
- Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7NCT06020755 · Phase 2 · Peking Union Medical College Hospital · starts Dec 1, 2024
- Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic NeoplasiaNCT05139095 · Phase 2 · Peking Union Medical College Hospital · starts Jan 27, 2022
- Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung NoduleNCT03785574 · Not applicable · Women's Hospital School Of Medicine Zhejiang University · starts Dec 24, 2018
- Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic…NCT03703271 · Phase 2 · Women's Hospital School Of Medicine Zhejiang University · starts Mar 1, 2019
- The French National Reference Centre of GTDNCT02892877 · Not reported · Hospices Civils de Lyon · starts Nov 1, 1999
Phase 3 9
- MethotrexateDihydrofolate reductase inhibitor
- DactinomycinDNA inhibitor
- Leucovorin
- CarboplatinDNA inhibitor
- CisplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- VincristineTubulin inhibitor
- CyclophosphamideDNA inhibitor
- Vitamin b complexHydatidiform mole
Phase 2 9
- AvelumabProgrammed cell death 1 ligand 1 other
- BevacizumabVascular endothelial growth factor A inhibitor
- PemetrexedThymidylate synthase inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- RivoceranibVascular endothelial growth factor receptor 2 inhibitor
- CarotuximabEndoglin inhibitor
- DostarlimabProgrammed cell death protein 1 antagonist
- CamrelizumabProgrammed cell death protein 1 antagonist
- ToripalimabProgrammed cell death protein 1 antagonist
Phase 1 or earlier 1
How its trials ended
35 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 6 whose ending is known, 50% met their primary endpoint, 0% missed it and 50% stopped early.
- Ongoing1543%
- Status unknown823%
- Completed, result not reported617%
- Met its primary endpoint39%
- Stopped: other or unclear26%
- Stopped: enrollment or feasibility13%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA